Marktanalyse - Liposarcoma - Pipeline Review, H2 2016

Global Markets Direct
12.2016
162 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Liposarcoma - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liposarcoma — Pipeline Review, H2 2016, provides an overview of the Liposarcoma (Oncology) pipeline landscape.

Liposarcoma is a malignant tumor of fatty tissue. Symptoms include noticeable lump or swelling, pain, weight loss and abdominal pain. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liposarcoma — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liposarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liposarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liposarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 3 and 2 respectively.Liposarcoma.

Liposarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liposarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Liposarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liposarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liposarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liposarcoma (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liposarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liposarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Liposarcoma Overview 7

Therapeutics Development 8

Pipeline Products for Liposarcoma - Overview 8

Liposarcoma - Therapeutics under Development by Companies 9

Liposarcoma - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Liposarcoma - Products under Development by Companies 13

Liposarcoma - Companies Involved in Therapeutics Development 14

Adaptimmune Therapeutics Plc 14

Amgen Inc 15

Cellceutix Corp 16

Eli Lilly and Company 17

Horizon Pharma Plc 18

Immune Design Corp 19

Karyopharm Therapeutics Inc 20

Merck & Co Inc 21

Mirati Therapeutics Inc 22

Novartis AG 23

Pfizer Inc 24

Liposarcoma - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 29

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

abemaciclib - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AMG-232 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CMB-305 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

everolimus - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

GSK-3377794 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

HDM-201 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

interferon gamma-1b - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Kevetrin - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

palbociclib - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

pazopanib hydrochloride - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

pembrolizumab - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

ribociclib succinate - Drug Profile 130

Product Description 130

Mechanism Of Action 130

R&D Progress 130

selinexor - Drug Profile 135

Product Description 135

Mechanism Of Action 135

R&D Progress 135

sirolimus - Drug Profile 152

Product Description 152

Mechanism Of Action 152

R&D Progress 152

sitravatinib - Drug Profile 153

Product Description 153

Mechanism Of Action 153

R&D Progress 153

Vimo-101 - Drug Profile 156

Product Description 156

Mechanism Of Action 156

R&D Progress 156

Liposarcoma - Dormant Projects 157

Liposarcoma - Discontinued Products 158

Liposarcoma - Product Development Milestones 159

Featured News & Press Releases 159

Nov 09, 2016: Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma 159

Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma 159

Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma 159

Appendix 161

Methodology 161

Coverage 161

Secondary Research 161

Primary Research 161

Expert Panel Validation 161

Contact Us 161

Disclaimer 162





List of Tables

Number of Products under Development for Liposarcoma, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Liposarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 14

Liposarcoma - Pipeline by Amgen Inc, H2 2016 15

Liposarcoma - Pipeline by Cellceutix Corp, H2 2016 16

Liposarcoma - Pipeline by Eli Lilly and Company, H2 2016 17

Liposarcoma - Pipeline by Horizon Pharma Plc, H2 2016 18

Liposarcoma - Pipeline by Immune Design Corp, H2 2016 19

Liposarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016 20

Liposarcoma - Pipeline by Merck & Co Inc, H2 2016 21

Liposarcoma - Pipeline by Mirati Therapeutics Inc, H2 2016 22

Liposarcoma - Pipeline by Novartis AG, H2 2016 23

Liposarcoma - Pipeline by Pfizer Inc, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Liposarcoma - Dormant Projects, H2 2016 157

Liposarcoma - Discontinued Products, H2 2016 158





List of Figures

Number of Products under Development for Liposarcoma, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Top 10 Targets, H2 2016 26

Number of Products by Stage and Top 10 Targets, H2 2016 26

Number of Products by Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus